Zai Lab EBITDA Margin 2016-2022 | ZLAB

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Zai Lab (ZLAB) over the last 10 years. The current EBITDA margin for Zai Lab as of March 31, 2022 is .
Zai Lab EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-03-31 $0.17B $-0.55B -319.88%
2021-12-31 $0.14B $-0.70B -482.64%
2021-09-30 $0.12B $-0.57B -496.52%
2021-06-30 $0.09B $-0.56B -648.28%
2021-03-31 $0.06B $-0.44B -758.62%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.927B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00